Despite the differences in data capture and outputs across clinical trials and real-world settings, this scoping review is the first to consolidate the published global experience and data for emicizumab in people with congenital hemophilia A. In line with the pivotal study outcomes that enabled the approval of emicizumab 6 years ago, these data support its acceptable tolerability, effectiveness, and positive impact on QoL, regardless of age, disease severity, or FVIII inhibitor status. The gene discussed is F8; the disease is hemophilia A.